Letter to the Editor: Induction therapy as a long-term commitment: Lessons from comparative outcomes of alemtuzumab and basiliximab

Induction immunosuppression in kidney transplantation requires a longitudinal perspective that extends beyond early rejection prevention to encompass long-term graft durability and patient safety. In response to the recent propensity score-matched study by Chukwu et al , complementary considerations are provided that address two underrecognized dimensions: Cumulative immunological burden and the downstream interaction between induction strategies and maintenance immunosuppression. Potent lymphoc